Results 71 to 80 of about 13,963,189 (308)

Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system

FEBS Letters, EarlyView.
Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley   +1 more source

Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis

BMJ Open Gastroenterology, 2020
Background Current guidelines recommend bismuth-containing quadruple therapy (BQT) and quinolone-containing therapy after failure of first-line Helicobacter pylori eradication therapy.
Hong-Zen Yeh, Yu-Kang Tu, Sung-Eun Kim, Yen-Lin Chang, Yu-Chun Tung, Jyh-Chin Yang, Ping-I Hsu, Ming-Fen Wu, Wen-Shyong Liou, Sz-Iuan Shiu   +9 more
doaj   +1 more source

Diversity and complexity in neural organoids

FEBS Letters, EarlyView.
Neural organoid research aims to expand genetic diversity on one side and increase tissue complexity on the other. Chimeroids integrate multiple donor genomes within single organoids. Self‐organising multi‐identity organoids, exogenous cell seeding, or enforced assembly of region‐specific organoids contribute to tissue complexity.
Ilaria Chiaradia, Madeline A. Lancaster
wiley   +1 more source

Switching multiple sclerosis patients with breakthrough disease to second-line therapy. [PDF]

PLoS ONE, 2011
BACKGROUND: Multiple sclerosis (MS) patients with breakthrough disease on immunomodulatory drugs are frequently offered to switch to natalizumab or immunosuppressants. The effect of natalizumab monotherapy in patients with breakthrough disease is unknown.
Tamara Castillo-Trivino, Ellen M Mowry, Alberto Gajofatto, Dorothee Chabas, Elizabeth Crabtree-Hartman, Bruce A Cree, Douglas S Goodin, Ari J Green, Darin T Okuda, Daniel Pelletier, Scott S Zamvil, Eric Vittinghoff, Emmanuelle Waubant   +12 more
doaj   +1 more source

Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives. [PDF]

, 2010
Despite the enormous progress made in scaling up antiretroviral therapy (ART) in sub-Saharan Africa, many challenges remain, not least of which are the identification and management of patients who have failed first-line therapy. Less than 3% of patients
Vic Arendt, Zengani Chirwa, van Oosterhout, Joep J, Zachariah, Rony, Steven D Reid, Anthony D Harries, Hosseinipour, Mina C, Kamoto, Kelita, Mina C Hosseinipour, Harries, Anthony D, Arendt, Vic, Chirwa, Zengani, Reid, Steven D, Joep J van Oosterhout, Kelita Kamoto, Jahn, Andreas, Schouten, Erik J, Andreas Jahn, Rony Zachariah, Erik J Schouten   +19 more
core   +1 more source

Exploring the Promise of Second-Line Chemotherapy in Biliary Tract Tumours: A Glimpse into Novel Treatment Approaches

, 2023
Biliary tract tumours, including bile duct, gallbladder, and ampulla of Vater malignancies, pose a rare but formidable oncologic challenge. Typically diagnosed at advanced stages, these tumours offer limited treatment options and dismal prognoses, with a
Raquel Fuentes Mateos, Paula Villalba Cuesta, Mercedes Avedillo Ruidiaz, Eva Ruiz Hispán, Angela Lamarca, Fuentes Mateos, R, Villalba Cuesta, P, Ruiz Hispán, E, Avedillo Ruidiaz, M, Lamarca, Angela   +9 more
core   +1 more source

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)

Therapeutics and Clinical Risk Management, 2008
Enriqueta Felip1, Rafael Rosell21Vall d’Hebron University Hospital, Barcelona, Spain; 2Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, SpainAbstract: NSCLC accounts for 80% of all cases of ...
Enriqueta Felip, Rafael Rosell
doaj  

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Liver organoids: modelling complexity in homeostasis and disease

FEBS Letters, EarlyView.
Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley   +1 more source